Trial Outcomes & Findings for Oxytocin and Social Cognitive Skills Groups (NCT NCT02918864)

NCT ID: NCT02918864

Last Updated: 2024-04-05

Results Overview

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Recruitment status

COMPLETED

Study phase

PHASE2

Target enrollment

40 participants

Primary outcome timeframe

Baseline and Week 12 (Endpoint)

Results posted on

2024-04-05

Participant Flow

Participant milestones

Participant milestones
Measure
ION-ASD
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in cognitive behavioral intervention (CBI) strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Overall Study
STARTED
20
20
Overall Study
Endpoint (Week 12)
19
19
Overall Study
1-month Follow-up (Week 16)
17
18
Overall Study
3-month Follow-up (Week 24)
16
17
Overall Study
COMPLETED
16
17
Overall Study
NOT COMPLETED
4
3

Reasons for withdrawal

Reasons for withdrawal
Measure
ION-ASD
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in cognitive behavioral intervention (CBI) strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Overall Study
Withdrawal by Subject
1
1
Overall Study
Lost to Follow-up
3
2

Baseline Characteristics

Data was missing for one participant's VIQ

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Total
n=40 Participants
Total of all reporting groups
Age, Categorical
<=18 years
20 Participants
n=20 Participants
20 Participants
n=20 Participants
40 Participants
n=40 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Age, Categorical
>=65 years
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Age, Continuous
9.30 years
STANDARD_DEVIATION 1.13 • n=20 Participants
9.20 years
STANDARD_DEVIATION 1.11 • n=20 Participants
9.25 years
STANDARD_DEVIATION 1.10 • n=40 Participants
Sex: Female, Male
Female
1 Participants
n=20 Participants
2 Participants
n=20 Participants
3 Participants
n=40 Participants
Sex: Female, Male
Male
19 Participants
n=20 Participants
18 Participants
n=20 Participants
37 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
7 Participants
n=20 Participants
5 Participants
n=20 Participants
12 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
13 Participants
n=20 Participants
13 Participants
n=20 Participants
26 Participants
n=40 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=20 Participants
2 Participants
n=20 Participants
2 Participants
n=40 Participants
Race (NIH/OMB)
American Indian or Alaska Native
1 Participants
n=20 Participants
0 Participants
n=20 Participants
1 Participants
n=40 Participants
Race (NIH/OMB)
Asian
2 Participants
n=20 Participants
1 Participants
n=20 Participants
3 Participants
n=40 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=20 Participants
0 Participants
n=20 Participants
0 Participants
n=40 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=20 Participants
3 Participants
n=20 Participants
7 Participants
n=40 Participants
Race (NIH/OMB)
White
7 Participants
n=20 Participants
10 Participants
n=20 Participants
17 Participants
n=40 Participants
Race (NIH/OMB)
More than one race
2 Participants
n=20 Participants
3 Participants
n=20 Participants
5 Participants
n=40 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants
n=20 Participants
3 Participants
n=20 Participants
7 Participants
n=40 Participants
CCC-2 Nonverbal Communication
8.80 units on a scale
STANDARD_DEVIATION 4.28 • n=20 Participants
8.75 units on a scale
STANDARD_DEVIATION 3.26 • n=20 Participants
8.77 units on a scale
STANDARD_DEVIATION 3.75 • n=40 Participants
CCC-2 Social Relations
8.30 units on a scale
STANDARD_DEVIATION 3.80 • n=20 Participants
7.60 units on a scale
STANDARD_DEVIATION 2.33 • n=20 Participants
7.95 units on a scale
STANDARD_DEVIATION 3.13 • n=40 Participants
Griffith Empathy Measure
12.65 units on a scale
STANDARD_DEVIATION 19.02 • n=20 Participants
22.05 units on a scale
STANDARD_DEVIATION 20.20 • n=20 Participants
17.35 units on a scale
STANDARD_DEVIATION 19.94 • n=40 Participants
RMET, % correct
63.57 percentage of correct items
STANDARD_DEVIATION 14.96 • n=20 Participants
58.93 percentage of correct items
STANDARD_DEVIATION 19.82 • n=20 Participants
61.25 percentage of correct items
STANDARD_DEVIATION 17.49 • n=40 Participants
DANVA2, % correct
65.23 percentage of correct items
STANDARD_DEVIATION 16.32 • n=20 Participants
65.86 percentage of correct items
STANDARD_DEVIATION 11.92 • n=20 Participants
65.55 percentage of correct items
STANDARD_DEVIATION 14.11 • n=40 Participants
Verbal IQ
96.30 units on a scale
STANDARD_DEVIATION 18.16 • n=20 Participants • Data was missing for one participant's VIQ
99.84 units on a scale
STANDARD_DEVIATION 18.24 • n=19 Participants • Data was missing for one participant's VIQ
98.03 units on a scale
STANDARD_DEVIATION 18.05 • n=39 Participants • Data was missing for one participant's VIQ
ADHD CASI-5 T-score
69.80 T-score
STANDARD_DEVIATION 14.24 • n=20 Participants
69.70 T-score
STANDARD_DEVIATION 9.56 • n=20 Participants
69.75 T-score
STANDARD_DEVIATION 11.97 • n=40 Participants
Social Responsiveness Scale-2 (SRS-2)
71.25 T-score
STANDARD_DEVIATION 11.09 • n=20 Participants
69.50 T-score
STANDARD_DEVIATION 8.43 • n=20 Participants
70.38 T-score
STANDARD_DEVIATION 9.76 • n=40 Participants
Caregiver Strain Questionnaire-Global Strain (CGSQ)
2.52 units on a scale
STANDARD_DEVIATION 0.79 • n=20 Participants
2.24 units on a scale
STANDARD_DEVIATION 0.51 • n=20 Participants
2.38 units on a scale
STANDARD_DEVIATION 0.67 • n=40 Participants

PRIMARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (baseline)
0.12 z-score
Standard Error 0.14
-0.14 z-score
Standard Error 0.14
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (week 12)
-0.26 z-score
Standard Error 0.14
-0.16 z-score
Standard Error 0.14

PRIMARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Behavior Impairment (SBI) Composite
-0.03 scores/week
Standard Error 0.01
0.00 scores/week
Standard Error 0.01

PRIMARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (baseline)
0.11 z-score
Standard Error 0.13
-0.14 z-score
Standard Error 0.14
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (week 16)
-0.29 z-score
Standard Error 0.14
-0.14 z-score
Standard Error 0.14

PRIMARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Behavior Impairment (SBI) Composite
-0.03 scores/week
Standard Error 0.01
0.00 scores/week
Standard Error 0.01

PRIMARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (baseline)
0.04 z-score
Standard Error 0.14
-0.16 z-score
Standard Error 0.14
Change From Baseline in Social Behavior Impairment (SBI) Composite
Estimated mean (week 24)
-0.21 z-score
Standard Error 0.15
-0.08 z-score
Standard Error 0.15

PRIMARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SBI is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SBI is a composite score based on Soorya et al. (2015) which identified measures that comprise this metric. Scores from the Children's Communication Checklist-2 (CCC-2) Social Relations and Nonverbal Communication subscales and the Griffith Empathy Measure (GEM) were standardized as z-scores using the sample means and standard deviations at baseline. CCC-2 subscale scores and reversed GEM total scores were used so higher z-scores reflect more impairment across measures. The SBI outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SBI z-score equals 0; higher individual scores indicate relatively more impairment in social behavior skills. Larger, negative slopes represent improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Behavior Impairment (SBI) Composite
-0.01 scores/week
Standard Error 0.01
0.00 scores/week
Standard Error 0.00

PRIMARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (baseline)
0.06 z-score
Standard Error 0.18
-0.08 z-score
Standard Error 0.18
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (week 12)
0.37 z-score
Standard Error 0.18
0.16 z-score
Standard Error 0.19

PRIMARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Cognition (SC) Composite
0.03 scores/week
Standard Error 0.01
0.02 scores/week
Standard Error 0.01

PRIMARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (baseline)
0.06 z-score
Standard Error 0.18
-0.08 z-score
Standard Error 0.18
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (week 16)
0.57 z-score
Standard Error 0.17
0.25 z-score
Standard Error 0.18

PRIMARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Cognition (SC) Composite
0.03 scores/week
Standard Error 0.01
0.02 scores/week
Standard Error 0.01

PRIMARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (baseline)
0.10 z-score
Standard Error 0.17
-0.08 z-score
Standard Error 0.17
Change From Baseline in Social Cognition (SC) Composite
Estimated mean (week 24)
0.63 z-score
Standard Error 0.17
0.37 z-score
Standard Error 0.17

PRIMARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in SC is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. SC is a composite score, including the Reading the Mind in the Eyes Test (RMET) and the Diagnostic Analysis of Nonverbal Accuracy-2 (DANVA2), based on Soorya et al. (2015). RMET has 28 items rated correct/incorrect (total 0-28). DANVA2 contains 4 sets of 24 items rated correct/incorrect (total 0-96). Percent correct was calculated for each measure given the difference in denominators and to allow for administrative omissions. Percentages were standardized as z-scores using the sample means and standard deviations at baseline. The SC outcome was subsequently derived by averaging the z-scores. At baseline, the sample average SC z-score equals 0; higher individual scores reflect stronger skills on social cognitive tasks compared to lower scores. Larger, positive slopes indicate skill improvement.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Cognition (SC) Composite
0.02 scores/week
Standard Error 0.00
0.02 scores/week
Standard Error 0.00

SECONDARY outcome

Timeframe: Week 12 (Endpoint)

Population: If participants were missing CGI-I ratings at week 12 (Facilitated Play: n=2), the rating from the last available visit (i.e., week 6) was used. Participants with scores of 3 or 4, indicating no significant change, were not included in the responder analyses (ION-ASD: n=12; Facilitated Play: n=12). One participant (Facilitated Play) had no data to carry forward. Additionally, two participants dropped out of the study (ION-ASD: n=1; Facilitated Play: n=1) and were excluded from the analyses.

Global Functioning will be assessed using the Clinical Global Impressions-Improvement (CGI-I) Scale. A study physician followed standard CGI protocols to evaluate global improvement at each time point based on all available sources of information (e.g., caregiver interviews, behavior rating forms). The CGI-I employs a 7-point scale with the lowest score, 1, indicating the best outcome and the highest score, 7, indicating the worst outcome. Participants receiving scores of 1 (very much improved) or 2 (much improved) were considered responders. Participants receiving scores of 5 (minimally worse), 6 (much worse), or 7 (very much worse) were considered non-responders; note, no participant received a score worse than 5 which was used as the cut-off for non-responders. Participants receiving scores of 3 (minimally improved) or 4 (no change) were considered to show no significant change and omitted from the analysis.

Outcome measures

Outcome measures
Measure
ION-ASD
n=7 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=6 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 12 (Endpoint)
Responder (scores 1-2)
7 Participants
5 Participants
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 12 (Endpoint)
Non-responder (score 5-7)
0 Participants
1 Participants

SECONDARY outcome

Timeframe: Week 16 (1-month follow-up)

Population: If participants were missing CGI-I ratings at week 16 (ION-ASD: n=1; Facilitated Play: n=5), the rating from the last available visit (i.e., 5 from week 12 and 1 from week 6) was used. Participants with scores of 3 or 4, indicating no significant change, were not included in the responder analyses (ION-ASD: n=10; Facilitated Play: n=12). Additionally, from baseline to week 16, five participants dropped out of the study (ION-ASD: n=3; Facilitated Play: n=2) and were excluded from the analyses.

Global Functioning will be assessed using the Clinical Global Impressions-Improvement (CGI-I) Scale. A study physician followed standard CGI protocols to evaluate global improvement at each time point based on all available sources of information (e.g., caregiver interviews, behavior rating forms). The CGI-I employs a 7-point scale with the lowest score, 1, indicating the best outcome and the highest score, 7, indicating the worst outcome. Participants receiving scores of 1 (very much improved) or 2 (much improved) were considered responders. Participants receiving scores of 5 (minimally worse), 6 (much worse), or 7 (very much worse) were considered non-responders; note, no participant received a score worse than 5 which was used as the cut-off for non-responders. Participants receiving scores of 3 (minimally improved) or 4 (no change) were considered to show no significant change and omitted from the analysis.

Outcome measures

Outcome measures
Measure
ION-ASD
n=7 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=6 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 16 (1-month Follow-up)
Responder (score 1-2)
4 Participants
4 Participants
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 16 (1-month Follow-up)
Non-responder (score 5-7)
3 Participants
2 Participants

SECONDARY outcome

Timeframe: Week 24 (3-month follow-up)

Population: If participants were missing CGI-I ratings at week 24 (ION-ASD: n=2), the rating from the last available visit (i.e., week 16) was used. Participants with scores of 3 or 4, indicating no significant change, were not included in the responder analyses (ION-ASD: n=6; Facilitated Play: n=11). Additionally, from baseline to week 24, seven participants dropped out of the study (ION-ASD: n=4; Facilitated Play: n=3) and were therefore excluded from the analyses.

Global Functioning will be assessed using the Clinical Global Impressions-Improvement (CGI-I) Scale. A study physician followed standard CGI protocols to evaluate global improvement at each time point based on all available sources of information (e.g., caregiver interviews, behavior rating forms). The CGI-I employs a 7-point scale with the lowest score, 1, indicating the best outcome and the highest score, 7, indicating the worst outcome. Participants receiving scores of 1 (very much improved) or 2 (much improved) were considered responders. Participants receiving scores of 5 (minimally worse), 6 (much worse), or 7 (very much worse) were considered non-responders; note, no participant received a score worse than 5 which was used as the cut-off for non-responders . Participants receiving scores of 3 (minimally improved) or 4 (no change) were considered to show no significant change and omitted from the analysis.

Outcome measures

Outcome measures
Measure
ION-ASD
n=10 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=6 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 24 (3-month Follow-up)
Responder (score 1-2)
7 Participants
3 Participants
Number of Responder and Non-responder Participants Based on CGI-I Scores at Week 24 (3-month Follow-up)
Non-responder (score 5-7)
3 Participants
3 Participants

SECONDARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (baseline)
70.83 T-score
Standard Error 2.16
69.50 T-score
Standard Error 2.22
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (week 12)
66.48 T-score
Standard Error 2.38
68.79 T-score
Standard Error 2.39

SECONDARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Functioning (SRS-2)
-.36 scores/week
Standard Error 0.21
-.06 scores/week
Standard Error 0.21

SECONDARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (baseline)
70.88 T-score
Standard Error 2.01
69.56 T-score
Standard Error 2.07
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (week 16)
65.42 T-score
Standard Error 2.01
68.69 T-score
Standard Error 2.11

SECONDARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Functioning (SRS-2)
-.34 scores/week
Standard Error 0.12
-0.05 scores/week
Standard Error 0.13

SECONDARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (baseline)
69.42 T-score
Standard Error 1.96
69.13 T-score
Standard Error 2.00
Change From Baseline in Social Functioning (SRS-2)
Estimated mean (week 24)
67.84 T-score
Standard Error 2.05
69.74 T-score
Standard Error 2.11

SECONDARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Social Responsiveness Scale (SRS-2) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The SRS-2 is a caregiver reported measure of social behavior in the general population (3-18 yo) used to assess social functioning. The SRS-2 contains 65 items rated on a 4-point scale (1/not true to 4/almost always true). Scores are recoded 0-3 and totaled for a raw score. Raw scores are converted to T-scores based on age and sex. T-scores have a population mean of 50 with a standard deviation of 10. T-scores 60-65 indicate mild social impairment, 66-75 moderate deficits, and above 76 severe deficits strongly associated with autism. Higher SRS-2 T-scores indicate greater severity of social impairment. Larger, negative slopes reflect a greater reduction in severity.

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Social Functioning (SRS-2)
-.07 scores/week
Standard Error 0.09
0.03 scores/week
Standard Error 0.09

SECONDARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (baseline)
2.52 units on a scale
Standard Error 0.16
2.24 units on a scale
Standard Error 0.16
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (week 12)
2.28 units on a scale
Standard Error 0.16
2.23 units on a scale
Standard Error 0.16

SECONDARY outcome

Timeframe: Baseline and Week 12 (Endpoint)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Quality of Life (CGSQ)
-0.02 units on a scale/week
Standard Error 0.02
0.00 units on a scale/week
Standard Error 0.02

SECONDARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (baseline)
2.52 units on a scale
Standard Error 0.15
2.25 units on a scale
Standard Error 0.15
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (week 16)
2.19 units on a scale
Standard Error 0.15
2.15 units on a scale
Standard Error 0.15

SECONDARY outcome

Timeframe: Baseline and Week 16 (1-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Quality of Life (CGSQ)
-0.02 units on a scale/week
Standard Error 0.01
-0.01 units on a scale/week
Standard Error 0.01

SECONDARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (baseline)
2.50 units on a scale
Standard Error 0.15
2.22 units on a scale
Standard Error 0.15
Change From Baseline in Quality of Life (CGSQ)
Estimated mean (week 24)
2.11 units on a scale
Standard Error 0.16
2.22 units on a scale
Standard Error 0.16

SECONDARY outcome

Timeframe: Baseline and Week 24 (3-month follow-up)

Population: All participants contributed to the intent to treat (ITT) model.

The change from baseline in the Caregiver Strain Questionnaire (CGSQ) is represented by the slope of each group. The primary outcome is the difference between groups in this rate of change or the group\*time interaction. The CGSQ was used to assess quality of life. The CGSQ is a parent-rated questionnaire designed for parents of children and adolescents with emotional and behavioral disorders. It includes 21 items rated on a 5-point problem scale (1 = not at all to 5 = very much) rating subjective internal, subjective external, and objective strain. A global measure of strain can be calculated by averaging the scores together. Higher CGSQ scores indicate greater strain. Larger, negative slopes reflect a greater reduction in strain (i.e., improvement in score).

Outcome measures

Outcome measures
Measure
ION-ASD
n=20 Participants
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 Participants
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Rate of Change From Baseline in Quality of Life (CGSQ)
-0.02 units on a scale/week
Standard Error 0.01
0.00 units on a scale/week
Standard Error 0.01

Adverse Events

ION-ASD

Serious events: 0 serious events
Other events: 20 other events
Deaths: 0 deaths

Facilitated Play

Serious events: 1 serious events
Other events: 20 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
ION-ASD
n=20 participants at risk
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 participants at risk
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Psychiatric disorders
Impulsivity
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Aggression
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Anxiety
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Irritable
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Mood lability
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.

Other adverse events

Other adverse events
Measure
ION-ASD
n=20 participants at risk
ION-ASD integrates targeted dosing of intranasal oxytocin and social cognitive skills group training curriculum, Seaver-NETT (Nonverbal communication, Emotion recognition, Theory of mind Training). Oxytocin: This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social Cognitive Skills Training: Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
Facilitated Play
n=20 participants at risk
The active comparison condition is a facilitated play therapy group. Facilitated Play Therapy: The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
Immune system disorders
Allergic reaction
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Ear and labyrinth disorders
Ear pain
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Eye disorders
Visual change
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Abdominal pain
20.0%
4/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
25.0%
5/20 • Number of events 7 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Change in appetite
35.0%
7/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
60.0%
12/20 • Number of events 14 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Constipation
30.0%
6/20 • Number of events 9 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
25.0%
5/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Cramping
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Diarrhea
25.0%
5/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Indigestion
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Large and frequent stools
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Loose stools
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Nausea/vomitting
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
General disorders
Change in sleep
35.0%
7/20 • Number of events 7 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
40.0%
8/20 • Number of events 13 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
General disorders
Change in speech
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Infections and infestations
Fever
20.0%
4/20 • Number of events 4 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
25.0%
5/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Infections and infestations
Infection
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 7 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Infections and infestations
Loss of tooth
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Infections and infestations
Toothache
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Musculoskeletal and connective tissue disorders
Back pain
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Musculoskeletal and connective tissue disorders
Joint pain
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Musculoskeletal and connective tissue disorders
Muscle ache
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
25.0%
5/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Clumsy
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Dizziness
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Fatigue
15.0%
3/20 • Number of events 4 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Headache
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Hyperactivity/Impulsivity
30.0%
6/20 • Number of events 8 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
45.0%
9/20 • Number of events 11 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Staring episode
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Abnormal thoughts
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Aggression
40.0%
8/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
35.0%
7/20 • Number of events 9 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Anxiety
35.0%
7/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
50.0%
10/20 • Number of events 14 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Confused
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Depression
20.0%
4/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Irritable
80.0%
16/20 • Number of events 24 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
65.0%
13/20 • Number of events 24 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Mood lability
50.0%
10/20 • Number of events 16 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
35.0%
7/20 • Number of events 9 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Poor Concentration
40.0%
8/20 • Number of events 8 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
35.0%
7/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Nose picking
5.0%
1/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Pulling on lip skin
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Repetitive behavior/speech
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Sassy - talking back
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Self-injurious behavior
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Fingernail picking
30.0%
6/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
45.0%
9/20 • Number of events 11 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Hair pulling
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Skin picking
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Stereotypic movement
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Suicidal thoughts
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Tearful
40.0%
8/20 • Number of events 8 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Tics
25.0%
5/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Renal and urinary disorders
Enuresis
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Renal and urinary disorders
Polydipsia, polyuria
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Clearing throat
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Cough
15.0%
3/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
30.0%
6/20 • Number of events 8 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Epistaxis
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
15.0%
3/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Runny nose
35.0%
7/20 • Number of events 8 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
30.0%
6/20 • Number of events 10 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Shortness of breath
10.0%
2/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
25.0%
5/20 • Number of events 7 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Sore throat
20.0%
4/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 5 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Wheezing
10.0%
2/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
10.0%
2/20 • Number of events 3 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Skin and subcutaneous tissue disorders
Eczema
35.0%
7/20 • Number of events 9 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Skin and subcutaneous tissue disorders
Rash
30.0%
6/20 • Number of events 7 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
20.0%
4/20 • Number of events 6 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Infections and infestations
Flu
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Psychiatric disorders
Low self esteem
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Odynophagia
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Skin and subcutaneous tissue disorders
Itching
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Social circumstances
Social withdrawal
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Nervous system disorders
Poor concentration
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Gastrointestinal disorders
Increase in flatulence
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
5.0%
1/20 • Number of events 1 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
Respiratory, thoracic and mediastinal disorders
Upper respiratory infection
0.00%
0/20 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.
10.0%
2/20 • Number of events 2 • 24 weeks
Systematic assessment of adverse events (AEs) occurred via trained clinician administration of a safety questionnaire (Adverse Event Form) to caregivers typically every other week beginning at week 1. AEs reported by caregivers' calls outside these visits were recorded as non-systematic. Note all severe AEs were for a single participant in the control (Facilitated Play) group. No AEs were rated as related to study drug.

Additional Information

Dr. Latha Valluripalli Soorya

Rush University Medical Center

Phone: (312) 942-6238

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place